secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001048477-24-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)
--------------------------------------------------------------------------------

- FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).
- VOXZOGO net revenues $146M in Q4'23 (+118% Q/Q) and $470M for FY'23 (+178% YoY); 2,613 children treated at year-end.
- Q4'23 total revenues $646.2M (+20% YoY); GAAP net income $20.4M vs $0.2M loss in Q4'22.
- 2024 guidance: double-digit total revenue growth, non-GAAP operating margin expansion, EPS growing faster than revenue.
- FDA approved VOXZOGO for children under 5; ~70% of new US starts from that age group in Q4'23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/0001048477-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/bmrn-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001048477-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer